(BGM) Qilian International - Ratings and Ratios

Exchange: NASDAQ • Country: China • Currency: USD • Type: Common Stock •

BGM: Pharmaceuticals, Medicine, Licorice, Fertilizers, Animal Health Products

BGM Group Ltd, formerly known as Qilian International Holding Group Limited, is a China-based pharmaceutical and agrochemical company listed on the NASDAQ under the ticker symbol BGM. Since its incorporation in 2019, the company has specialized in manufacturing and distributing active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and related by-products. Its product portfolio includes licorice derivatives, such as Gan Di Xin, used as an antitussive and expectorant, and Qilian Shan Licorice Extract, which serves as a key ingredient for pharmaceutical companies producing traditional licorice tablets. The company also offers Qilian Shan licorice liquid extract, a primary component for manufacturing compound licorice oral solutions.

BGM Group Ltd provides veterinary and human healthcare solutions through its Qilian Shan oxytetracycline tablets and APIs, which are used to prevent and treat diseases in livestock and humans. Additionally, the company produces TCMD products, including Ahan antibacterial paste for treating chronic skin conditions and heparin sodium preparations for cardiovascular and cerebrovascular medications. Its non-pharmaceutical offerings include Zhu Xiaochang sausage casings for culinary applications and Xiongguan organic and organic-inorganic compound fertilizers, designed to enhance crop yields and soil health. The company operates from its headquarters in Chengdu, Sichuan Province, China, and maintains a strong focus on research, development, and distribution across its diversified product lines.

Based on the provided and , BGM Group Ltd is currently trading at $10.59 with a 20-day average volume of 9,214 shares. Its short-term moving averages (SMA 20: $10.07, SMA 50: $9.91) suggest a recent uptrend, while the long-term SMA 200 ($7.16) indicates significant growth over the past year. The Average True Range (ATR) of 1.13 reflects moderate volatility. From a fundamental perspective, the company has a market capitalization of $46.83 million, with a price-to-book (P/B) ratio of 1.08 and a price-to-sales (P/S) ratio of 1.57. However, the negative return on equity (RoE) of -3.38% signals potential profitability challenges.

Based on the and , BGM Group Ltd is expected to experience continued volatility over the next three months. The stock may test resistance near $12.00, driven by its recent upward momentum, but downside risks remain due to its negative RoE and the broader market conditions. The SMA 50 and SMA 200 indicate long-term bullish sentiment, but short-term price movements will likely be influenced by trading volumes and market sentiment. Investors should monitor the companys ability to improve profitability and its strategic initiatives to expand its product portfolio.

Additional Sources for BGM Stock

BGM Stock Overview

Market Cap in USD 47m
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
GiC Sub-Industry Pharmaceuticals
IPO / Inception 2024-08-12

BGM Stock Ratings

Growth 5y -38.4%
Fundamental -24.4%
Dividend 1.0%
Rel. Strength Industry 202
Analysts -
Fair Price Momentum 9.42 USD
Fair Price DCF -

BGM Dividends

Dividend Yield 12m 0.00%
Yield on Cost 5y %
Annual Growth 5y -100.00%
Payout Consistency 1.0%

BGM Growth Ratios

Growth Correlation 3m 50.5%
Growth Correlation 12m 94.9%
Growth Correlation 5y -66.2%
CAGR 5y -31.85%
CAGR/Max DD 5y -0.33
Sharpe Ratio 12m -0.30
Alpha 196.46
Beta 0.22
Volatility 79.98%
Current Volume 6.1k
Average Volume 20d 4.9k
What is the price of BGM stocks?
As of March 14, 2025, the stock is trading at USD 9.80 with a total of 6,085 shares traded.
Over the past week, the price has changed by -7.42%, over one month by -5.41%, over three months by +13.95% and over the past year by +201.54%.
Is Qilian International a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Qilian International is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of -24.36 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BGM as of March 2025 is 9.42. This means that BGM is currently overvalued and has a potential downside of -3.88%.
Is BGM a buy, sell or hold?
Qilian International has no consensus analysts rating.
What are the forecast for BGM stock price target?
According to ValueRays Forecast Model, BGM Qilian International will be worth about 10.2 in March 2026. The stock is currently trading at 9.80. This means that the stock has a potential upside of +4.08%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 10.2 4.1%